NASDAQ$CCCC
C4 Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023, and recent business highlights.
C4 Therapeutics reported a revenue of $2.7 million and a net loss of $35.9 million for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $286.7 million as of June 30, 2023, expected to provide runway into the second half of 2025.
- Established Exclusive Licensing Agreement for CFT8919 with Betta Pharmaceuticals in Greater China for NSCLC.
- U.S. IND Cleared for CFT8919.
- Ongoing Phase 1/2 Clinical Trials of CFT7455 and CFT8634 Continue to Progress; Phase 1 Dose Escalation Data Expected 2H 2023.
- Strengthened Leadership Team with Appointments of Len Reyno, M.D., as Chief Medical Officer, and Mary Christian, Pharm.D., as Senior Vice President, Regulatory.
Headline financials
Revenue & EPS history
C4 Therapeutics · Revenue · Quarterly
$2.66M
Revenue by segment
C4 Therapeutics · $2.66M total across 1 segment · Q2 2023
- Collaboration agreements$2.66M-80.7%100.0%
Forward guidance
C4T expects to share clinical updates from the dose escalation portion of the ongoing Phase 1/2 trials for its two lead programs, CFT7455 in multiple myeloma and CFT8634 in synovial sarcoma and SMARCB1-null cancers in the second half of the year.
Tailwinds
- Present Phase 1 dose escalation data from the Phase 1/2 clinical trial of Arm B1, evaluating CFT7455 as a monotherapy in MM, in the second half of 2023.
- Present Phase 1 dose escalation data from the Phase 1/2 clinical trial for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+1.0%
Avg return
Earnings day
+4.1%
Avg return
5 days after
-2.2%
Avg return
30 days after
38%
9 / 24 earnings
Positive
+24.0%
Q4 2023
Best reaction
-10.0%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +13.0% | — | |
| Q4 2025 | +0.4% | +17.4% | +13.9% | |
| Q3 2025 | -2.0% | -10.0% | +8.0% | |
| Q1 2025 | -0.7% | -1.4% | +21.7% | |
| Q4 2024 | -1.9% | -10.2% | -34.0% | |
| Q3 2024 | +1.4% | +10.1% | -17.7% | |
| Q1 2024 | +0.1% | -9.1% | -31.4% | |
| Q4 2023 | +24.0% | +34.5% | +13.4% | |
| Q3 2023 | -6.0% | +21.5% | +7.4% | |
| Q2 2023 | -1.7% | -3.1% | -33.8% | |
| Q1 2023 | +4.8% | +5.6% | +8.0% | |
| Q4 2022 | -10.0% | -11.0% | -40.2% | |
| Q3 2022 | -8.1% | -6.4% | -11.8% | |
| Q2 2022 | +16.7% | +6.9% | -8.7% | |
| Q1 2022 | -8.1% | -19.3% | -24.4% | |
| Q4 2021 | +13.9% | +13.9% | +24.3% | |
| Q3 2021 | -4.6% | -7.3% | -23.6% | |
| Q2 2021 | +8.0% | +5.6% | +33.6% | |
| Q1 2020 | -0.6% | +7.4% | +20.4% | |
| Q1 2021 | -0.6% | +7.4% | +20.4% | |
| Q2 2020 | +9.6% | +7.2% | -19.8% | |
| Q3 2019 | -3.7% | +8.3% | +8.3% | |
| Q4 2019 | -3.7% | +8.3% | +8.3% | |
| Q3 2020 | -3.7% | +8.3% | +8.3% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro